Autopsy report · NCT04908735

Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant

“Study closed due to slow enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 4 years before it stopped.
• 7 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Children's Hospital Medical Center, Cincinnati

Sponsor type

University, hospital or other

Conditions

Hematopoietic Stem Cell Transplant (HSCT); Bronchiolitis Obliterans (BO)

Interventions

Ruxolitinib

Participants

7

Sites

2

Countries

United States

Trials that died the same way

• Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer
  “The study was closed to enrollment due to slow accrual.” (92% match in meaning)
• Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
  “Study closed before total enrollment met.” (87% match in meaning)
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
  “Study stopped due to slow enrollment” (87% match in meaning)
• A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
  “Closed due to slow enrollment” (86% match in meaning)
• Reconstruction Flaps for Nasal Surgical Wounds RCT
  “Study closed before enrollment could begin.” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.